Validation of Nijmegenâ€“Bethesda assay modifications during replacement therapy and facilitate inhibitor sur

Journal of Thrombosis and Haemostasis

10, 1055-1061

DOI: 10.1111/j.1538-7836.2012.04705.x

Citation Report

#	Article	IF	Citations
1	Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors. Thrombosis Research, 2013, 132, 735-741.	0.8	9
2	Diagnosis and treatment of factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in congenital haemophilia: (4th edition). British Journal of Haematology, 2013, 160, 153-170.	1.2	192
4	Comparison of clotâ€based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. Journal of Thrombosis and Haemostasis, 2013, 11, 1300-1309.	1.9	56
5	Specific Factor Inhibitor Testing. , 2013, , 815-818.		0
6	Coagulation factor VII variants resistant to inhibitory antibodies. Thrombosis and Haemostasis, 2014, 112, 972-980.	1.8	17
7	Contemporary Approaches to Hemophilia. , 2014, , .		0
8	A Public Health Approach to the Prevention of Inhibitors in Hemophilia. American Journal of Preventive Medicine, 2014, 47, 669-673.	1.6	10
9	Acquired hemophilia: a case report and review of the literature. International Journal of Laboratory Hematology, 2014, 36, 398-407.	0.7	28
10	Laboratory testing for factor inhibitors. Haemophilia, 2014, 20, 94-98.	1.0	27
11	Preâ€analytical heat treatment and a <scp>FVIII ELISA</scp> improve Factor <scp>VIII</scp> antibody detection in acquired haemophilia A. British Journal of Haematology, 2014, 166, 953-956.	1.2	24
13	A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia, 2014, 20, 230-237.	1.0	37
14	Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1935-1939.	1.9	530
16	Pearls and pitfalls in factor inhibitor assays. International Journal of Laboratory Hematology, 2015, 37, 52-60.	0.7	21
17	Allergic reaction in a cohort of haemophilia A patients using plasmaâ€derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII. Haemophilia, 2015, 21, e281-5.	1.0	7
18	Characteristics of hemophilia patients with factor <scp>VIII</scp> inhibitors detected by prospective screening. American Journal of Hematology, 2015, 90, 871-876.	2.0	11
19	Improving the performance of factor VIII inhibitor tests in hemophilia A. Thrombosis Research, 2015, 136, 1047-1048.	0.8	6
20	Heat treatment of samples improve the performance of the Nijmegenâ€“Bethesda assay in hemophilia A patients undergoing immune tolerance induction. Thrombosis Research, 2015, 136, 1280-1284.	0.8	14
21	ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. Journal of Immunological Methods, 2015, 426, 114-119.	0.6	10

#	Article	IF	Citations
22	Characterization of the antiâ€factorÂVIII immunoglobulin profile in patients with hemophiliaÂA by use of a fluorescenceâ€based immunoassay. Journal of Thrombosis and Haemostasis, 2015, 13, 47-53.	1.9	32
23	Blood coagulation factor XIII and factor XIII deficiency. Blood Reviews, 2016, 30, 461-475.	2.8	101
24	Quality laboratory issues in bleeding disorders. Haemophilia, 2016, 22, 84-89.	1.0	7
25	A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity. International Journal of Laboratory Hematology, 2016, 38, 639-647.	0.7	7
26	Survey of the antiâ€"factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescenceâ€based immunoassay. Journal of Thrombosis and Haemostasis, 2016, 14, 1931-1940.	1.9	10
27	Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood, 2016, 127, 3439-3449.	0.6	27
28	Diagnosis of factor XIII deficiency. Hematology, 2016, 21, 430-439.	0.7	28
29	Treatment burden, haemostatic strategies and real world inhibitor screening practice in nonâ€severe haemophilia A. British Journal of Haematology, 2017, 176, 796-804.	1.2	21
30	Inhibitor screening in nonâ€severe haemophilia patients; a major challenge. British Journal of Haematology, 2017, 176, 683-685.	1.2	1
31	The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	10
32	Toward functional assays for assessing the significance of antiâ€ABO(H) alloantibodies. Transfusion, 2017, 57, 491-494.	0.8	7
33	Detection and Measurement of Factor Inhibitors. Methods in Molecular Biology, 2017, 1646, 295-304.	0.4	15
35	Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. Journal of Thrombosis and Haemostasis, 2017, 15, 1971-1976.	1.9	16
36	Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia, 2018, 24, 487-491.	1.0	22
37	Reagent substitutions in the Centers for Disease Control and Prevention Nijmegenâ€Bethesda assay for factor <scp>VIII</scp> inhibitors. Haemophilia, 2018, 24, e116-e119.	1.0	4
38	Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. Journal of Thrombosis and Haemostasis, 2018, 16, 1132-1140.	1.9	58
39	Laboratory testing for factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in haemophilia: A review. Haemophilia, 2018, 24, 186-197.	1.0	45
40	Identification of aggregates in therapeutic formulations of recombinant fullâ€length factor VIII products by sedimentation velocity analytical ultracentrifugation. Journal of Thrombosis and Haemostasis, 2018, 16, 303-315.	1.9	11

#	Article	IF	Citations
41	Prevalence of factor VIII inhibitors among Afghan patients with hemophilia A. Blood Coagulation and Fibrinolysis, 2018, 29, 697-700.	0.5	5
42	Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A. International Journal of Laboratory Hematology, 2018, 40, 561-568.	0.7	5
43	Antibodies to FVIII. , 2018, , 119-134.		0
44	Hemophilia A. , 2018, , 103-137.		2
45	The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha. Haemophilia, 2018, 24, e372-e375.	1.0	5
46	Commonly setting biological standards in rare diseases. Expert Opinion on Orphan Drugs, 2019, 7, 305-314.	0.5	1
47	Reagent substitution in the chromogenic Bethesda assay for factor <scp>VIII</scp> inhibitors. Haemophilia, 2019, 25, e342-e344.	1.0	2
48	Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions. Transfusion Medicine Reviews, 2019, 33, 217-224.	0.9	23
49	Monitoring of blood coagulation with nonâ€contact drop oscillation rheometry. Journal of Thrombosis and Haemostasis, 2019, 17, 1345-1353.	1.9	4
50	Haemophilia in CÃ´te dâ€™Ivoire (the Ivory Coast) in 2017: Extensive data collection as part of the World Federation of Hemophiliaâ€™s twinning programme. Haemophilia, 2019, 25, 236-243.	1.0	13
51	Heat inactivation of extended halfâ€life factor VIII concentrates. Haemophilia, 2019, 25, e130-e131.	1.0	5
52	Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. Genome Biology, 2019, 20, 276.	3.8	50
53	Specific Factor Inhibitor Testing. , 2019, , 789-792.		1
54	Laboratory evaluation of hemostasis. , 2020, , 765-792.		1
55	Inhibitor epidemiology and geneticâ€related risk factors in people with haemophilia from CÃ´te dâ€™Ivoire. Haemophilia, 2020, 26, 79-85.	1.0	3
56	Evaluation of preâ€analytic heat treatment protocol used in the CDC Nijmegenâ€Bethesda assay for heat inactivation of extended halfâ€life haemophilia treatment products. Haemophilia, 2020, 26, e28-e30.	1.0	6
57	Crossâ€reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A. Haemophilia, 2020, 26, 1181-1186.	1.0	5
58	Clinical utility of sample preheat treatment in a modified Nijmegenâ€Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A singleâ€centre fourâ€year experience. Haemophilia, 2020, 26, e300-e307.	1.0	1

#	Article	IF	Citations
59	Combined antiâ€CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors. Journal of Thrombosis and Haemostasis, 2020, 18, 848-852.	1.9	10
60	Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A. Thrombosis Research, 2020, 195, 51-54.	0.8	5
61	The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B. Haemophilia, 2020, 26, 735-740.	1.0	0
62	Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 2205-2208.	1.9	26
63	Laboratory testing in hemophilia: Impact of factor and nonâ€factor replacement therapy on coagulation assays. Journal of Thrombosis and Haemostasis, 2020, 18, 1242-1255.	1.9	32
64	Optimization of the detection of inhibitory autoantibodies against the VWFâ€cleaving protease ADAMTS13 with an automated chemiluminescent ADAMTS13 activity immunoassay. International Journal of Laboratory Hematology, 2021, 43, 290-297.	0.7	2
65	Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab. International Journal of Laboratory Hematology, 2021, 43, e84-e86.	0.7	10
66	Evaluation of antiâ€factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents. Haemophilia, 2021, 27, e40-e50.	1.0	1
67	Daratumumab rapidly reduces highâ€titre factor VIII inhibitors in haemophilia A patients during lifeâ€threatening haemorrhages. Haemophilia, 2021, 27, e155-e159.	1.0	5
68	Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey. Haemophilia, 2021, 27, 490-499.	1.0	2
69	B cellâ€“activating factor modulates the factor VIII immune response in hemophilia A. Journal of Clinical Investigation, 2021, 131, .	3.9	10
70	The chromogenic Bethesda assay and the Nijmegenâ€Bethesda assay for factor VIII inhibitors in hemophilia A patients: Are they equivalent?. Journal of Thrombosis and Haemostasis, 2021, 19, 1835-1837.	1.9	3
71	Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay. Haemophilia, 2021, 27, 823-829.	1.0	2
72	Hemophilia A (Factor VIII Deficiency). Hematology/Oncology Clinics of North America, 2021, 35, 1117-1129.	0.9	7
73	Detailed analysis of antiâ€emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. Journal of Thrombosis and Haemostasis, 2021, 19, 2938-2946.	1.9	15
74	Approach to a Child with Hemophilia B and Anaphylaxis to Factor IX. , 2020, , 35-48.		0
75	Evaluation of CDCâ€™s Hemophilia Surveillance Program â€" Universal Data Collection (1998â€“2011) and Community Counts (2011â€“2019), United States. MMWR Surveillance Summaries, 2020, 69, 1-18.	18.6	26
76	Guidance for establishing a factor VIII testing protocol for the myriad of factor VIII products. International Journal of Laboratory Hematology, 2022, 44, 414-423.	0.7	2

#	Article	IF	Citations
77	Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy. International Journal of Hematology, 2022, , .	0.7	1
78	Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report. Journal of Medical Case Reports, 2022, 16, 177.	0.4	1
79	Factor IX antibodies and tolerance in hemophilia B in the Nordic countries â€“ The impact of F9 variants and complications. Thrombosis Research, 2022, 217, 22-32.	0.8	1
80	Stability of specimens for use in the Centers for Disease Control and Prevention assays for factor VIII and IX inhibitors. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12806.	1.0	1
82	Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegenâ€“Bethesda assay. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12799.	1.0	1
83	Hemophilia A: Emicizumab monitoring and impact on coagulation testing. Advances in Clinical Chemistry, 2023, , 273-315.	1.8	1
87	Congenital Factor XIII Deficiency, Diagnosis, and Management. , 2023, , 363-375.		0
88	Hemophilia A: Diagnosis and Management. , 2023, , 107-143.		0